Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 vs Chemotherapy in Platinum-resistant Recurrent Epithelial Ovarian Cancer
NCT06994195Phase 3Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2025
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Biokin Pharmaceutical. Started Aug 2025; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06994195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06994195.